The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers 非小細胞肺癌におけるEGFR遺伝子変異と臨床病理学的因子の関係

この論文にアクセスする

この論文をさがす

著者

    • 徳毛, 誠樹 トクモ, マサキ

書誌事項

タイトル

The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers

タイトル別名

非小細胞肺癌におけるEGFR遺伝子変異と臨床病理学的因子の関係

著者名

徳毛, 誠樹

著者別名

トクモ, マサキ

学位授与大学

岡山大学

取得学位

博士 (医学)

学位授与番号

甲第3003号

学位授与年月日

2005-06-30

注記・抄録

博士論文

PURPOSE: Recent studies reported that clinical responsiveness to gefitinib was associated with somatic mutation of epidermal growth factor receptor (EGFR) gene in non-small cell lung cancers (NSCLC). Here, we investigated the relationship between EGFR mutation and clinicopathologic features. EXPERIMENTAL DESIGN: EGFR mutational status of 120 NSCLCs was determined mainly in EGFR exons 18 to 21 by direct sequence and correlated with clinicopathologic parameters. RESULTS: EGFR mutations were present in 38 cases (32%) and the majority of mutations were in-frame deletions of exon 19 (19 cases) and a missense mutation in exon 21 (18 cases). EGFR mutations were frequently associated with adenocarcinoma (P < 0.0001), never smoker (P < 0.0001), and female gender (P = 0.0001). Of interest, increasing smoke exposure was inversely related to the rate of EGFR mutation (P < 0.0001). Multivariate analysis showed that smoking and histology were independent variables. Furthermore, gender difference was observed for the mutational location (P = 0.01) dominance of exon 19 for males and exon 21 for females. Twenty-one cases were treated with gefitinib and found that EGFR mutation was significantly related to gefitinib responsiveness (P = 0.002). In addition, median survival times of patients with and without EGFR mutations treated with gefitinib were 25.1 and 14.0 months, respectively. Patients with EGFR mutations had approximately 2-fold survival advantage; however, the difference was not significant. CONCLUSIONS: We show that EGFR mutations were significantly related to histology and smoke exposure and were a strong predictive factor for gefitinib responsiveness in NSCLC.

1アクセス

各種コード

  • NII論文ID(NAID)
    500000335147
  • NII著者ID(NRID)
    • 8000000336062
  • 本文言語コード
    • eng
  • NDL書誌ID
    • 000008050407
  • データ提供元
    • 機関リポジトリ
    • NDL ONLINE
ページトップへ